Drug intelligence / Profile preview

TT201

Development stage: Preclinical
Lead developer: Tempo Therapeutics
Administration: Intradermal, Subcutaneous

Overview

TT201 is a preclinical-stage microporous annealed particle (MAP) hydrogel scaffold developed by Tempo Therapeutics (formerly Tempo Buyer) for medical aesthetics, specifically for the treatment of facial lipoatrophy. Utilizing Tempo's proprietary MAP technology, TT201 is designed as an injectable synthetic biomaterial that promotes soft-tissue restoration and volume recovery. Unlike traditional solid dermal fillers, the MAP technology creates a microporous microenvironment that supports rapid cellular infiltration, vascularization, and tissue integration while minimizing scarring and host immune rejection.

Other names: TT201 - Medical AestheticsTT-201 - Medical AestheticsTT 201 - Medical Aesthetics

Beyond the preview

Go deeper on TT201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT201.

Explore the full profile